Skip to content
VectorGene
en

CHGB · Partner-reported service scope

Methylation-Based Early Cancer Detection

Blood-based gene methylation analysis for early cancer detection, applicable to lung, thyroid, liver, colorectal, gastric and oesophageal cancer.

Partner-reported scope
6+ cancer types
Method
Blood-based methylation
Automated sample transport in a laboratory. Illustrative stock photograph.
Automated sample transport in a laboratory

CHGB · Partner-reported

Service capabilities

The following scope is reported by the partner. Quantities describe the partner portfolio and do not represent VectorGene’s own track record.

Lung cancer
Thyroid cancer
Liver cancer
Colorectal cancer
Gastric cancer
Oesophageal cancer

Explore the related platform.

Advanced genomic testing platforms for precision oncology, inherited disease analysis, pathogen sequencing, microbiome analysis and population-level genomic programmes.

Genomics & NGS Testing
Varies by jurisdiction

Diagnostic testing is regulated differently in every jurisdiction. VectorGene supports local validation and accreditation; the regulatory dossier remains owned by the local institution.

Explore services in this category.

Read each service’s complete scope and regulatory note. These links help you explore the portfolio; programme-specific suitability requires feasibility assessment.

Evaluate screening utility beyond a detectable signal.

A proposed methylation test needs a clearly defined population and intended use. Institutions should request assay-specific evidence and examine the complete pathway after a positive, negative or unresolved result. Technical performance and benefit in an asymptomatic screening programme are separate questions.

NCI explains that the effectiveness of multi-cancer detection tests for screening people without symptoms remains uncertain and requires evaluation in randomised clinical trials.

NCI: Screening Tests

External references explain the wider context. They do not verify or endorse the supplied VectorGene or partner offering.

Questions for the programme brief

  1. For which population and use?

    Define age, risk, symptoms and whether the proposal concerns screening, diagnostic investigation or research.

  2. Which evidence is available?

    Request prospective data for the proposed assay and population, including false results, stage distribution and follow-up completeness.

  3. What follows a positive result?

    Review diagnostic work-up, referral capacity, unresolved findings and how harms and outcomes would be evaluated.

What to prepare for review
  • Intended population and assay specification
  • Assay-specific validation and clinical evidence
  • Follow-up and outcome-evaluation plan

Working environments

Laboratory preparation and analysis.

Illustrative stock photography provides context for the people, processes and working environments behind this capability.

Purple pipette and laboratory tubes. Illustrative stock photograph.
Purple pipette and laboratory tubes
Laboratory technician performing a barcode scan. Illustrative stock photograph.
Laboratory technician performing a barcode scan
Scientist analysing DNA fragments using agarose gel. Illustrative stock photograph.
Scientist analysing DNA fragments using agarose gel
Gloved hands use a pipette to prepare laboratory samples.
Molecular sample preparation

Start a conversation

Discuss Methylation-Based Early Cancer Detection

This service will be retained as context for your enquiry. Choose the platform or support area you want to develop at your institution.
Partner with us